NZYM B Novozymes A/S Class B

Trading by management and close relations of management

Trading by management and close relations of management

The Executive Leadership Team members eligible for the Novozymes A/S 2022-2024 incentive program has on February 26, 2025, received the allocated shares. An overview of the number and value of shares allotted is provided on the attached file.

Attachment



EN
27/02/2025

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please see attached the full announcement. Attachment

March 3, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management The Executive Leadership Team members eligible for the Novozymes A/S 2022-2024 incentive program has on February 26, 2025, received the allocated shares. An overview of the number and value of shares allotted is provided on the attached file. Attachment

February 27, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

12M 2024: Novonesis delivers strong full-year results and expects cont...

12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025 Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%.  COPENHAGEN, Denmark – February 26, 2025. In the 2024 financial year, Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin at 36.1%. The sales growth is driven by both Food & Health Biosolutions and Planetary Health Biosolutions. Volumes have increased by ~6% with pricing contribu...

February 26, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

12M 2024 Company announcement

12M 2024 Company announcement 2024 organic pro forma sales growth of 8%, with pro forma adjusted EBITDA margin of 36.1%. 2025 outlook of 5-8% organic pro forma sales growth and 37-38% adjusted EBITDA margin.    2024 organic pro forma sales growth of 8% (Q4: 7%) and 8% on IFRS reported basis (Q4 7%). Food & Health Biosolutions at 7%, and Planetary Health Biosolutions at 9%.2024 pro forma adjusted EBITDA margin of 36.1% (2H 36.8%), with 35.2% for Food & Health Biosolutions and 36.8% for Planetary Health Biosolutions. 2024 adjusted EBITDA margin on IFRS reported base of 36.2% (2H 36.8%).2024 ...

February 26, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Change to the Executive Leadership Team

Change to the Executive Leadership Team Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Ester Baiget, President & CEO comments: “I want to thank Jacob for his strong leadership and commitment to Novonesis and our Food & Beverage Biosolutions business. Jacob has played an instrumental role in Novonesis. As a result of his contribution, the Food & Beverage Biosolutions business in Novonesis rests on a solid foundation with an extraordinary team and is uniq...

February 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch